Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A00009712" target="_blank" >RIV/61989592:15110/09:00009712 - isvavai.cz</a>

Alternative codes found

RIV/61989592:15110/09:00009742

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.

Original language description

Mutations of BCR-ABL tyrosine kinase domain represent the most frequently identified and best-studied mechanism of chronic myeloid leukemia (CML) resistance to the treatment with tyrosine kinase inhibitors (TKIs). In previously reported patients with F317L BCR-ABL kinase domain mutation response to dasatinib treatment was invariably poor. We describe a CML patient in chronic phase with F317L mutation identified shortly after the initiation of dasatinib therapy,following previous imatinib failure. Despite a continual persistence of the F317L mutation, the patient achieved a complete cytogenetic and a major molecular response after 4 and 6 months of dasatinib treatment, respectively, and maintained the response for more than 20 months of followup.Possible explanations for this long-term favourable response may include immune-mediatedeffects associated with dasatinib therapy, elimination of proliferative advantage of F317L-mutant cells through inhibition of Src family of kinases (SFK) or

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NS9949" target="_blank" >NS9949: The role of in vitro sensitivity to tyrosine kinase inhibitors estimation in management of patients with chronic myeloid leukemia</a><br>

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia Research

ISSN

0145-2126

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

4

Country of publishing house

GB - UNITED KINGDOM

Number of pages

3

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—